Loading...

Conducted a regulatory risk-based audit for a Chinese pharmaceutical company

For a Chinese pharmaceutical company, lawyers of the practice conducted an audit of regulatory risks associated with products that were imported into Russia. The tasks before our lawyers included: assessing historical and potential regulatory and commercial risks as well as the risks of complaints from consumers and also issuing recommendations for how such risks can be mitigated.

As a result, the client was made aware of the pertinent risks associated with its products, including with regard to import duties, lawsuits from consumers and so on. The legal memo the client received was used to prepare the company for an IPO.

Office:  

Back to the list

15.12.2025
Pepeliaev Group has strengthened its position in the “PRO Bankruptcy Leaders” ranking of law firms
Read more
11.12.2025
Sergey Pepeliaev joins the working group of the Agency for Strategic Initiatives
Read more
05.12.2025
Pepeliaev Group has expanded its presence in the Pravo-300 ranking in 2025
Read more